BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, July 10, 2026
Breaking News: AI co-scientist performs biomedical research ‘at expert level’ in less timeBreaking News: AI co-scientist performs biomedical research ‘at expert level’ in less timeBreaking News: Science fiction realized: BCI tech is here
Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
BioWorld Science, Cancer RSS Feed RSS

Cancer

Nanjing Mingde New Drug Research presents new ER-α degradation inducers

Aug. 20, 2024
Nanjing Mingde New Drug Research Co. Ltd. has divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding agent coupled to an estrogen receptor α (ER-α; ESR1)-targeting moiety via linker. They are reported to be useful for the treatment of breast cancer.
Read More
Cancer

Beijing Zheyuan Technology divulges new PLK1 inhibitors

Aug. 20, 2024
Beijing Zheyuan Technology Co. Ltd. has synthesized serine/threonine-protein kinase PLK1 (STPK13) inhibitors reported to be useful for the treatment of cancer and sepsis.
Read More
Cancer

Suzhou Zion Pharma Technology patents new GTPase KRAS inhibitors

Aug. 20, 2024
Suzhou Zion Pharma Technology Co. Ltd. has disclosed GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Read More
Lab glassware and antibodies art concept
Immuno-oncology

Adcendo licenses rights to Multitude’s ADC targeting tissue factor

Aug. 20, 2024
Adcendo ApS and Multitude Therapeutics Inc. have signed a licensing agreement for the development of a highly differentiated antibody-drug conjugate (ADC) targeting tissue factor, designated ADCE-T02.
Read More
Drug R&D concept image.
Cancer

Cumulus Oncology licenses small molecules from GPR68 drug discovery project with Leadxpro

Aug. 20, 2024
Cumulus Oncology Ltd. has announced key milestones, in partnership with collaborator Leadxpro AG, in the companies’ protein structure-driven GPR68 drug discovery project.
Read More
Cancer

IMPDH2 blockade promotes tumor cell apoptosis in pediatric hepatoblastoma

Aug. 20, 2024
Prior work has unveiled increased levels of inosine monophosphate dehydrogenase 2 (IMPDH2) expression correlating with tumor progression and poor prognosis in several diseases. A team of researchers in China have now aimed to study IMPDH2’s role in hepatoblastoma.
Read More
Cancer

Roche scientists discover new GTPase KRAS mutant inhibitors

Aug. 19, 2024
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described GTPase KRAS mutant inhibitors, particularly KRAS G12C mutant, reported to be useful for the treatment of cancer.
Read More
Cancer

Shanghai Institute of Materia Medica patents new PARP inhibitors for cancer

Aug. 19, 2024
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has disclosed phthalazinone or quinazolinone derivatives acting as poly(ADP-ribose) polymerase (PARP) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Disruptor of β-catenin pathway contributes to colorectal tumor suppression

Aug. 19, 2024
The hyperactivation of the Wnt/β-catenin signaling pathway plays a central role in the progression and expansion of colorectal cancer (CRC). The suppression of this pathway may contribute to the control of the proliferation, survival and metastasis of CRC.
Read More
Cancer

Beijing Tide Pharmaceutical describes new PROTACs for cancer

Aug. 16, 2024
Beijing Tide Pharmaceutical Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising a cereblon E3 ubiquitin ligase binding moiety coupled to tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) targeting agents through linkers reported to be useful for the treatment of cancer.
Read More
Previous 1 2 … 292 293 294 295 296 297 298 299 300 … 3715 3716 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 9, 2026.
  • 3D rendering of an antibody drug conjugate

    ‘Target-high but uptake-defective’ state identified in ADC resistance

    BioWorld
    Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
  • Illustration of brain and brain waves, concept of focal seizure

    Hyperexcitability may be joint problem in epilepsy, dementia

    BioWorld
    The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
  • Modius Spero wearable neuromodulation device

    Neurovalens granted FDA approval for PTSD therapy for US veterans

    BioWorld
    Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
  • Art concept for medical research

    FENS 2026: Shedding light on the sheddome

    BioWorld
    At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing